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SUMMARY
Progress in understanding themolecular pathogenesis of humanmyeloproliferative disorders (MPDs) has led
to guidelines incorporating genetic assayswith histopathology during diagnosis. Advances in flow cytometry
have made it possible to simultaneously measure cell type and signaling abnormalities arising as a conse-
quence of genetic pathologies. Using flow cytometry, we observed a specific evoked STAT5 signaling signa-
ture in a subset of samples from patients suspected of having juvenile myelomonocytic leukemia (JMML), an
aggressive MPD with a challenging clinical presentation during active disease. This signature was a specific
feature involving JAK-STAT signaling, suggesting a critical role of this pathway in the biologicalmechanismof
this disorder and indicating potential targets for future therapies.INTRODUCTION
Myeloproliferative disorders (MPDs) are clonal malignancies
characterized by overproduction of immature and mature mye-
loid cells showing organ infiltration. In particular, juvenile myelo-
monocytic leukemia (JMML) and chronic myelomonocytic
leukemia (CMML) are characterized by malignant transformation
in the stem cell compartment with clonal proliferation of progeny
that variably retain the capacity to differentiate (Arico et al., 1997;
Onida et al., 2002). Children suspected of having JMML often
present with failure to thrive, fever, infection, splenomegaly,
and a high white blood cell count with monocytosis. Current
diagnostic criteria are imprecise and consist of major and minorrequirements that are in large part based on excluding other con-
ditions (Niemeyer et al., 1997). The major requirements include
an absolute monocytosis > 1,000/ml, fewer than 20% bone mar-
row blasts, and absence of the t(9;22) or BCR-ABL fusion gene.
Patients must also meet two of the minor criteria, including an
elevated fetal hemoglobin level for age, circulating myeloid pre-
cursors, a total white blood cell count > 10,000/ml, and in vitro
hypersensitivity to granulocyte-macrophage colony-stimulating
factor (GM-CSF).
Extensive molecular data implicate genetic lesions that dereg-
ulate Ras signaling as key initiating events in JMML, with studies
showing that 60% of patients harbor an oncogenic mutation in
PTPN11, NRAS, or KRAS while another 15% have clinicalSIGNIFICANCE
Recent advances have enabled simultaneous measurement of cell type and cell signals in primary populations using flow
cytometry. This technique allows us to answer the question, ‘‘Can we track oncogenic cell populations from diagnosis
through disease evolution via signaling?’’ Doing so in an era of using specific inhibitors against components of key signal
transduction pathways will be necessary to assess treatment effects in human patients to further adapt therapies as cancer
cells alter their signaling in response to these treatments. This work uses such an approach to follow patients over time and
shows that disease status in juvenile myelomonocytic leukemia (JMML)—at diagnosis, remission, relapse, and transforma-
tion—is indicated by a subset of cells with an abnormal signaling profile.
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type NF1 allele in their diseased bone marrow (Emanuel, 2004;
Flotho et al., 2007). Patients with the myeloproliferative subtype
of CMML exhibit NRAS, KRAS, and JAK2 mutations (Levine
et al., 2005; Onida et al., 2002). A cellular characteristic of both
JMML and CMML is the formation of abnormal numbers of gran-
ulocyte-macrophage colony-forming units (CFU-GM) in methyl-
cellulose cultures containing subsaturating concentrations of
GM-CSF (Cambier et al., 1997; Emanuel et al., 1991), which
has led to suggestions that alterations downstream of the acti-
vated GM-CSF receptor collaborate to drive inappropriate cell
growth and survival. One important primary signaling event fol-
lowing binding of GM-CSF to the GM-CSF receptor is activation
of the JAK-STAT pathway (Paukku and Silvennoinen, 2004).
JAK2 transphosphorylates the b common chain of the GM-
CSF receptor, which creates docking sites for adaptors and sig-
nal relay molecules, resulting in activation of Ras and down-
stream Ras effectors including ERK and S6 ribosomal protein
(see Figure S1 available online) (Irish et al., 2004; Kunz and Ibra-
him, 2003; McCubrey et al., 2000; Rane and Reddy, 2002; Shuai
and Liu, 2003).
CMML is an adult MPD that is clinically similar to JMML and
shares certain genetic features such the frequent presence of
RAS mutations (Onida et al., 2002). JAK2 mutations are rare in
JMML and only slightly more common in CMML patients (Levine
et al., 2005; Steensma et al., 2005; Zecca et al., 2007), whereas
PTPN11 mutations are almost nonexistent in CMML (Loh et al.,
2005). Both JMML and CMML can progress to M4 or M5 acute
myeloid leukemia (AML), which comprise the myelomonocytic
(M4) and monocytic (M5) subtypes (Arico et al., 1997). Further-
more, somatic NRAS, KRAS, and PTPN11 mutations occur fre-
quently in the M4 and M5 subtypes of AML (Bacher et al.,
2006; Loh et al., 2004).
Currently, it takes up to 3–4 weeks to confirm a suspected di-
agnosis of JMML with a CFU-GM assay. As early allogeneic he-
matopoietic stem cell transplant (HSCT) is the only potentially
curative therapy for JMML (Locatelli et al., 2005), it is important
to quickly and accurately diagnose these patients in order to de-
liver appropriate therapy in a timely fashion. In addition, monitor-
ing disease burden during treatment is challenging in patients
with JMML due to imprecise clinical definitions of response. Cur-
rent allele-specific PCR methodologies to detect minimal resid-
ual disease are only applicable to approximately 60% of patients
(Archambeault et al., 2008). Importantly, because JMML and
CMML exhibit considerable cellular heterogeneity, it has been
difficult to elucidate the biologic features of cells that contribute
to the cancer phenotype in vivo and of precursor populations
that might carry genetic lesions predisposing cells to an onco-
genic fate.
Assays for identifying therapeutic agents and assessing effi-
cacy in these patients based on the biochemical consequences
of lesions in the GM-CSF and Ras signaling networks are few.
Recent advances in flow cytometry, however, have made it pos-
sible to simultaneously measure cell type and aberrant cell sig-
nals (Irish et al., 2006) arising as a consequence of these lesions.
We used this approach to profile signaling at the single-cell level
(Irish et al., 2004; Van Meter et al., 2007), including molecules
downstream of the GM-CSF receptor and molecules closely as-
sociated with Ras signaling, for the presence of primary JMML
336 Cancer Cell 14, 335–343, October 7, 2008 ª2008 Elsevier Inc.cells with altered signaling behavior that correlate with disease
physiology. Our cohort of 52 samples included patients diag-
nosed with JMML, healthy individuals, infants with other
MPDs, and children initially suspected of having JMML who
were subsequently diagnosed with other disorders.
RESULTS
A Flow Cytometry-Based Signaling Assay Can Be Used
to Measure GM-CSF Hypersensitivity
We used phosphospecific flow cytometry (Irish et al., 2004,
2006) after exposure to increasing concentrations of GM-CSF
to interrogate evoked signaling responses in JMMLcells. In a first
test of GM-CSF-induced phosphorylation of STAT5, we ob-
served the dose-dependent appearance of a population of cells
in a JMML bone marrow sample compared to normal healthy
bone marrow (Figure 1A). This leukemia was also assessed via
the traditional methylcellulose assay and exhibited hypersensi-
tive colony formation (defined as clusters of >50 cells) at increas-
ing concentrations of GM-CSF (Figures 1C and 1D), as
described previously (Emanuel et al., 1991).
We then investigated 11 additional JMML samples at diagno-
sis and compared these leukemias to normal samples (n = 8),
other childhood MPDs (these cases included 8 patients with
Noonan syndrome/MPD [NS/MPD] or Down’s syndrome with
transient myeloproliferative disorders [DS/TMD]), and 4 children
with an initial clinical suspicion of JMML who were subsequently
found to have another diagnosis. We observed an induced phos-
phorylated STAT5 (p-STAT5) population in the majority of JMML
samples that were exposed to low levels of GM-CSF, but not in
the other samples interrogated. The data were quantified as a
relative percentage of p-STAT5-responsive cells as outlined in
the Experimental Procedures (Figure 1B).
p-STAT5 Response to Low Doses of GM-CSF Indicates
JMML Status
The combination of CD38 and p-STAT5 best stratified the
GM-CSF-hyperresponsive population, which was measurable
in both peripheral blood and bonemarrow samples. Representa-
tive samples from the patient cohort are shown in Figure 2A.
The signature was present in both fresh and previously frozen
primary samples (details for each sample are provided in
Table S1).
p-STAT5 Signaling Cells in JMML Samples Are
of Myeloid Origin and Require JAK2 Activity
Immunophenotyping revealed that the p-STAT5-responsive
cells were of myeloid origin (CD33+CD14+), CD34, and
CD38lo (Figure S2). The involvement of JAK-specific activation
of the p-STAT5 response in these cells was first confirmed by
exposing primary samples to a chemical JAK2 inhibitor for
30 min before GM-CSF stimulation at 10 ng/ml for 15 min
(Figure S3). Similarly, exposing JMML cells to a 5 mM concentra-
tion of the oral JAK2 inhibitor XL019 (Exelixis) inhibited STAT5
and ERK phosphorylation in response to a saturating concentra-
tion of GM-CSF, whereas the MEK inhibitor CI-1040 (Pfizer)
failed to alter the p-STAT5 response despite inhibiting p-ERK
(Figure 2B).
Figure 1. Hyperphosphorylation of STAT5 Is Seen in Primary JMML Cells at Low Concentrations of GM-CSF
The diagnosis of juvenilemyelomonocytic leukemia (JMML) is confirmed through an in vitro granulocyte-macrophage colony-forming unit (CFU-GM) assay show-
ing colony formation at low concentrations of granulocyte-macrophage colony-stimulating factor (GM-CSF). Colonies form over 2 weeks at various doses of GM-
CSF.
(A) Phosphospecific flow cytometry-based assay demonstrating that GM-CSF hypersensitivity can be measured via phosphorylated STAT5 (p-STAT5). Primary
cells from JMML and normal bonemarrow (BM) were stimulated at varying concentrations of GM-CSF. The JMML samples show a subset of cells responding via
p-STAT5 at low concentrations of GM-CSF.
(B) Increase in p-STAT5 response to GM-CSF concentration was quantified as a function of maximal response. A higher percentage of p-STAT5+ cells were pres-
ent at 0.16 and 0.32 ng/ml GM-CSF concentrations in JMML samples (n = 12) than in healthy samples (n = 8), samples with Noonan syndrome or Down’s
syndrome-related transient myeloproliferative disorders (‘‘Other MPD,’’ n = 8), or non-MPD samples that were initially suspected to be JMML (n = 4).
(C) Colonies formed in a JMML sample and a normal sample at increasing doses of GM-CSF. Samples shown are the same ones measured using phosphospe-
cific flow cytometry in (A).
(D) Colony formation from JMML patients (n = 10) was quantified as a function of maximum colony growth, plotted over varying concentrations of GM-CSF and
compared against growth from healthy samples (n = 6).
Error bars in (B) and (D) represent standard error of the mean (SEM).
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Percentile
To visualize the data set from all patients studied, we calculated
ratios of the 95th percentile of p-STAT5 activity to the unstimu-
lated sample and displayed the results in heat map format (see
Experimental Procedures). Eleven of twelve JMML samples
showed highly sensitive activation of p-STAT5 (at 0.32 ng/ml
GM-CSF) as compared to lack of activation in the majority of
the control specimens. Diagnostic samples from infants with
other MPDs, including those with NS/MPD and DS/TMD, did
not demonstrate a p-STAT5 population hyperresponsive to
GM-CSF (Figure 3A). In addition, samples obtained from children
suspected of having JMML but subsequently found to have
other disorders did not demonstrate the induced p-STAT5 pop-
ulation. The absence of the p-STAT5 signature in conditions that
are phenotypically similar to JMML highlights the importance of
the signaling disruptions that we observe specifically in JMML.
Overall, 11 of 12 JMML diagnostic samples showed a GM-
CSF-hypersensitive population, 7 of 8 healthy samples did not
show a GM-CSF-hypersensitive population, 8 of 8 NS/MPD or
DS/TMD samples did not show a GM-CSF-hypersensitive pop-ulation, and 4 samples from patients suspected of having
JMML but later found not to have a MPD did not show a GM-
CSF-hypersensitive population (Figure 3A). Based on this analy-
sis, the p-STAT5 diagnostic assay has a sensitivity of 91% and
a specificity of 95%. An unsupervised grouping of these patients
was calculated by normalizing the response of p-STAT5 (as
measured by the 95th percentile) to GM-CSF concentrations
within a patient (Figure 3D). Using this metric, samples with a re-
sponse > 40 showed a JMML-like evoked signaling pattern. Fur-
ther information about these samples is given in Table S1. Ele-
vated levels of p-ERK and basal activation of p-S6 were
detected in some JMML samples, but these alterations were
a less consistent feature of JMML than hypersensitive signaling
at the level of p-STAT5 (Figures S4–S7).
p-STAT5 Response to Low Doses of GM-CSF
Is Detectable in CMML and M4/M5 AML
We also analyzed evoked p-STAT5 responses in CMML and
AML and found that 5 of 5 samples from adults with CMML
and 4 of 8 samples from patients with AML showed a hyperre-
sponsive population (Figure 3C; Figures S8 and S9). In AML,
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at Diagnosis
(A) CD38 and p-STAT5 stratify the responsive population present in JMML peripheral blood (PB) and bone marrow (BM) samples at diagnosis.
(B) Exposure to an oral JAK2 inhibitor, XL019, abrogated both the p-STAT5 and p-ERK response while exposure to a MEK inhibitor, CI-1040, inhibited only the
p-ERK response.the presence of an aberrant p-STAT5 response to subtherapeu-
tic concentrations of GM-CSF correlated with the French-Amer-
ican-British M4/M5 morphologic subtype (n = 4) and was not
detected in non-M4/M5 AML samples (n = 4). The eight AML
samples were assessed for lesions in PTPN11, NRAS, KRAS,
and FLT3. The genotype data were less predictive of the signal-
ing phenotype than the cell type, as two patients with non-M4/
M5 AML who were found to harbor an FLT3 internal tandem
duplication (ITD) and one patient with an NRAS mutation did
not exhibit the p-STAT5 signature. Further information is given
in Tables S1 and S2.
Signaling Response Can Indicate Disease Status
To determine whether the signaling signature was maintained or
altered over time, we followed two JMML patients through a se-
ries of samples obtained at various time points during therapy. In
particular, patient HM1158 achieved clinical remission, under-
went matched unrelated HSCT, and remains in remission. The
p-STAT5-hyperresponsive population has been absent in this
patient’s remission samples (Figure 4). In contrast, patient
HM1394 responded poorly to chemotherapy, never achieved
complete clinical remission, and relapsed shortly after undergo-
ing a first matched related HSCT. Following a second HSCT, this
patient progressed to M4 AML. Over time, subsequent samples
demonstrated an increasing p-STAT5 response at low concen-
trations of GM-CSF (Figure 4). To further demonstrate that the
p-STAT5 population was of malignant origin, genomic DNA
was isolated from the responsive population after sorting on
338 Cancer Cell 14, 335–343, October 7, 2008 ª2008 Elsevier Inc.CD38 and p-STAT5 at 0.32 ng/ml of GM-CSF in a patient harbor-
ing a somatic NRASG12D mutation. These cells contained the
NRAS mutation, whereas DNA extracted from the patient’s
T cells did not (data not shown).
DISCUSSION
Based on the presence of Ras pathway mutations in JMML (re-
viewed in Emanuel, 2004; Flotho et al., 2007), the characteristic
GM-CSF hypersensitivity of myeloid progenitors isolated from
JMML patients in methylcellulose culture, and compelling data
from Kras, Nf1, and Ptpn11 mutant mice linking genetic lesions
found in JMML to MPD and GM-CSF hypersensitivity (Araki
et al., 2004; Braun et al., 2004; Chan et al., 2004; Le et al.,
2004; Mohi et al., 2005), we used phosphospecific flow cytome-
try to assay p-ERK and p-S6 levels in patient samples. The find-
ing that a small proportion of CD33+CD14+CD38lo cells exhibited
hyperphosphorylation of p-STAT5 in response to subsaturating
concentrations of GM-CSF was unexpected. Whereas studies
of JMML patient samples and mice lacking either Gmcsf or the
b common chain of the murine GM-CSF receptor (Birnbaum
et al., 2000; Kim et al., 2007) provide strong evidence that an ab-
errant response to GM-CSF is integral to the pathogenesis of
JMML, the role of STAT5 has not been explored.
Our data raise the intriguing possibility that Ras-GTP is up-
stream of JAK2-STAT5 activation in the aberrant response of
JMML cells to GM-CSF. Ras pathway mutations might potenti-
ate JAK-STAT signaling by stabilizing or directly activating the
Figure 3. The p-STAT5-Responsive Population Is Indicative of Active JMML
(A) Clinically similar myeloproliferative disorders (MPDs) such as Noonan syndrome/MPD and Down’s syndrome/TMD are distinguishable from JMML via phos-
phoflow cytometry. Eleven of twelve JMML patient samples at diagnosis showed a GM-CSF-hypersensitive population. Seven of eight normal bone marrow
samples did not have a GM-CSF-hypersensitive population.
(B) Postdiagnosis samples show a p-STAT5 response in patients who have relapsed or transformed into M4/M5 acute myeloid leukemia (AML). Samples in
remission do not show the p-STAT5 response.
(C) The signature was also present in chronic myelomonocytic leukemia (CMML, a similar disease to JMML that is diagnosed in adults) andM4/M5 AML (myeloid
leukemia with myelomonocytic and monocytic differentiation).
(D) Samples sorted by normalized p-STAT5 response at 0.32 ng/ml. Samples > 40 showed JMML activity (signaling profiles 1 and 2). Eight of twelve JMML
samples at diagnosis had a normalized p-STAT5 response > 95 (signaling profile 1).
Trans., transformation to AML; Remiss., remission; PMAIO, PMA/ionomyocin.
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SHP-2 phosphatase, which is deregulated by JMML-associated
mutations, is recruited to phosphorylated tyrosine residues on
the activated b subunit of the GM-CSF receptor and is essential
for efficient STAT5 activation in myeloid cells that are stimulated
with interleukin-3 (Yu et al., 2003). Ras localizes to activated re-
ceptor complexes, and elevated levels of Ras-GTP might in turn
increase the degree and/or duration of JAK2 kinase activity.
We considered the possibility that hyperactivation of Ras/Raf/
MEK/ERK signaling in JMML cells might overwhelm a negative
regulatory molecule that normally suppresses GM-CSF-induced
JAK-STAT signaling. If so, inhibitors of this effector pathway
would be expected to interfere with the hypersensitive response
of STAT5 to GM-CSF. However, exposing primary JMML cells to
CI-1040 failed to alter the p-STAT5 response despite inhibiting
p-ERK. As a number of reports have shown that STAT5 is essen-
tial for establishing murine MPDs, including Bcr-Abl-positive
chronic myelogenous leukemia (CML) and CMML (Baker et al.,
2007; Cain et al., 2007; Ilaria and Van Etten, 1996; Paukku and
Silvennoinen, 2004; Van Etten, 2004), understanding the bio-
chemical mechanism underlying elevated p-STAT5 levels in my-
eloid malignancies with mutations in Ras signaling genes has
therapeutic implications.We also observed discrepancies between p-STAT5 activation
in response to low concentrations of GM-CSF and a hypersensi-
tive pattern of CFU-GM colony growth in three types of patients.
This is perhaps not unexpected, as the CFU-GM assay interro-
gates a population of cultured myeloid progenitors that form col-
onies after 2 weeks, whereas phosphospecific flow cytometry
measures a specific biochemical response of a more mature
monocytoid cell population to a burst of GM-CSF. It is also im-
portant to recall that a hypersensitive pattern of CFU-GM colony
growth in methylcellulose is neither necessary nor sufficient to
establish a diagnosis of JMML. With these caveats in mind, the
rare patients who showed differences between the two assays
raise interesting questions that have implications for diagnosis
and disease management.
Infants with NS/MPD are an interesting group. Whereas mye-
loid progenitors from these patients display hypersensitivity to
GM-CSF in CFU-GM assays, we did not detect the p-STAT5 sig-
nature in our phosphoflow assay. Importantly, it is now recog-
nized that, like the transient MPD seen in neonates with DS,
the MPD that occurs in infants with NS usually resolves without
treatment (Bader-Meunier et al., 1997; Kratz et al., 2005). Current
management of these patients involves watchful waiting. Germ-
line PTPN11 mutations encode weaker gain-of-function alleles
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teria, including progenitor colony growth (Araki et al., 2004; Mohi
et al., 2005; Schubbert et al., 2006). Based on these data, it is
likely that phosphoflow cytometry provides amore specific read-
out of the rewired signaling networks found in JMML, an aggres-
sive clonal myeloid malignancy, versus the transient MPD that
occurs in patients with NS. An interesting question for future
studies is whether phosphoflow cytometry can prospectively
identify those rare infants with NS/MPD who will manifest an ag-
gressive clinical course.
We also encountered a child without NS (patient HM1753) who
met diagnostic criteria for JMML early in life but improved with-
out treatment. When we evaluated this patient at 2 years of age,
he demonstrated modest GM-CSF hypersensitivity but did not
exhibit the phosphoflow signature. Molecular analysis revealed
anNRASG13Dmutation. Interestingly, other cases of JMML asso-
ciated with somatic NRAS mutations have been reported to
spontaneously clinically regress over time (Flotho et al., 2008;
Matsuda et al., 2007) but retain their RAS lesions. The molecular
basis for this is unclear but could involve the initiating NRASmu-
tation occurring in a cell lacking unlimited self-renewal potential
(i.e., a non-stem cell). Alternatively, since Ras proteins with
amino acid substitutions at codon 13 exhibit higher intrinsic
GTPase activity than codon 12 mutant proteins (Ahmadian
et al., 1999), it is possible that somemutantRAS alleles are insuf-
ficiently activated to cause aggressive JMML. This possibility is
consistent with an infant with NS and a moderately activating
germline KRAST58I mutation who showed spontaneous regres-
sion of a JMML-like MPD during the first year of life (Schubbert
et al., 2006) and with the NS/MPD paradigm discussed above.
Importantly, our analysis of the patient with an NRASG13D muta-
tion further suggests that a normal phosphoflow signature may
identify children with NRAS and PTPN11 mutations who will
have a benign clinical course and can be observed closely
Figure 4. The p-STAT5-Responsive Population Disap-
pears in Remission and Reappears during Relapse
Cells from JMML patients were profiled at diagnosis and again
following a change in disease status. Both patients exhibited
the characteristic JMML signature of p-STAT5 hypersensitiv-
ity to low GM-CSF doses (0.16 and 0.32 ng/ml) at diagnosis.
Patient HM1394 responded poorly to upfront therapy, re-
lapsed, and eventually transformed toM4AML. As the disease
worsened, a greater percentage of cells were hyperrespon-
sive. In contrast, patient HM1158 achieved clinical remission
and no longer displayed the JMML signature.
without aggressive treatment. Further studies of
additional patients will be necessary to confirm
this hypothesis.
The only case in our groupwith aggressive JMML
who did not exhibit the characteristic GM-CSF/p-
STAT5 phosphoflow signature harbored
a KRASG12D mutation. In recent studies of addi-
tional cases, we have confirmed that the vast ma-
jority of children meeting the clinical criteria for
JMML exhibit aberrant p-STAT5 activation in re-
sponse to GM-CSF, with the exception of a second
patient with a KRASG12D mutation who did not
show this signaling abnormality. Although these data need to
be prospectively validated in a larger cohort study, they suggest
that the KRASG12D mutation, which is phenotypically aggressive
in murine models (Braun et al., 2004; Chan et al., 2004), is
less dependent upon JAK2-STAT5 signaling than other Ras
pathway mutations. Interestingly, phosphosignaling analysis of
c-kit+/lineagelo/ cells from KrasG12D mice with MPD did not re-
veal abnormal STAT5 activation by GM-CSF (data not shown;
Van Meter et al., 2007). Our data therefore raise the intriguing
possibility that myeloid malignancies with mutations in KRAS
show differential activation of p-STAT5 (and perhaps other
signaling molecules) compared to cells that express oncogenic
NRAS or PTPN11.
A recent publication of World Health Organization 2008 classi-
fication guidelines (Tefferi et al., 2007; Tefferi and Vardiman,
2008) suggests diagnostic approaches to combine molecular
pathogenesis along with histology for both classic and atypical
MPDs. Discoveries of somatic mutations in Ras signaling mole-
cules have improved diagnostic capabilities for JMML but are
still not universally applicable. In addition, following patients on
therapy remains challenging in the absence of tractable markers.
Our data imply that advances in proteomic and single-cell flow
cytometry technologies will add to the genetic mapping of these
disorders, allow tracking of rare cell populations that would be
difficult to observe in bulk assay approaches (RNA expression
or mass spectrometry), and allow us to measure specific activity
at the protein level. We have demonstrated the diagnostic value
of such information in JMML and CMML and anticipate that fur-
ther phosphoflow cytometry-based assays will allow for direct
measurements of the key signaling events required for disease
maintenance. Finally, the results suggest that JMML, CMML,
and M4/M5 AML are related entities in which hyperactive Ras
and aberrant JAK2-STAT5 signaling are early or initiating events
(Braun et al., 2004). As such, M4/M5 AML might be distinct from
340 Cancer Cell 14, 335–343, October 7, 2008 ª2008 Elsevier Inc.
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sions such as PML-RARA and AML1-ETO likely represent pri-
mary leukemogenic events (Gilliland and Griffin, 2002). This
has important therapeutic implications, as M4/M5 AML might
be highly dependent on Ras and JAK2-STAT5 signaling and
therefore sensitive to inhibitors of these pathways. Revealing
cell subpopulations associated with disease opens additional
avenues for measuring minimal residual disease, assessing the
biochemical effects of targeted therapies at the single-cell level,
and understanding drug action and mechanisms in diseases of
heterogeneous origins and manifestations in diverse patient
populations.
EXPERIMENTAL PROCEDURES
Sample Collection
Fresh bone marrow or peripheral blood samples were obtained from children
suspected of having JMML or another MPD related to a congenital syndrome,
including NS or DS. In addition, the following hematopoietic tissues were an-
alyzed in order to demonstrate the specificity of the JMML phosphoprotein
signature: (1) archived frozen bone marrow products from healthy sibling do-
nors for hematopoietic stem cell transplants, (2) normal bone marrow taken
from children suspected of having a metastatic solid tumor, (3) diagnostic
bone marrow or pheresis samples from children or adults with AML, and (4)
archived bone marrow or peripheral blood samples from adult patients with
CMML. All samples were obtained with informed consent. This study was ap-
proved by the UCSF Committee on Human Research. Samples were collected
in sodium heparin, andmononuclear cells were isolated according to standard
methods.
Frozen samples were cryopreserved in 90% FBS/10% DMSO. Table S1 in-
dicates fresh or frozen status of samples used for phosphoflow analysis; how-
ever, all colony assays were performed only using fresh material. Table S2 lists
cytogenetic information about the AML samples.
Genotyping
All patients referred for workup of a JMML diagnosis were genotyped for
PTPN11 exons 3 and 13, NRAS exons 1 and 2, and KRAS exons 1 and 2 ac-
cording to previously published methodologies (Kalra et al., 1994; Loh et al.,
2004; Meshinchi et al., 2003). Genomic DNA was prepared using Puregene re-
agents (QIAGEN). Data were also collected for family history of and World
Health Organization criteria for neurofibromatosis type 1. The eight patients
with AML were additionally genotyped for FLT3 ITD and FLT3 D835 according
to previously published methodologies (Meshinchi et al., 2003; Zwaan et al.,
2003).
CFU-GM Assay
Mononuclear cells were isolated from fresh bone marrow samples and resus-
pended in Iscove’s Modified Dulbecco’s Medium (IMDM) + 2% FBS. Cells
were suspended at a concentration of 200,000 cells/ml. 154 ml of the cell sus-
pension was added to a tubewith the following: 1.2mlMethoCult H4230meth-
ylcellulose (Stem Cell Technologies, Cat. 04230), 15 ml of 1003 penicillin/
streptomycin, 30.8 ml of human GM-CSF titration (PeproTech, Cat. 300-03),
diluted in water and IMDM to complete the tube volume to 1.54 ml. The solu-
tion was vortexed for 15 s and rested for 15 min. 1.1 ml was plated into a 353
10 mm Petri dish (BD Falcon, Cat. 351008) placed into a 150 3 15 mm Petri
dish (BD Falcon, Cat. 351058) with another dish containing sterile water, and
placed into an incubator at 37C, 5%CO2. After 14 days, plates were removed
from the incubator, and colonies (clusters of 50 cells or more) were counted
under amicroscope at 403magnification. Data are presented in Table S1. Hy-
persensitive growth (+2) corresponds to 50% of maximal growth, whereas
hypersensitive growth (+3) corresponds to maximal growth.
Cytokine Stimulation and Intracellular Phosphoprotein Analysis
Using Flow Cytometry
Reagents used for flow cytometry included 16% paraformaldehyde (EM
grade, Electron Microscopy Sciences, Cat. 15710), methanol (ElectronMicroscopy Sciences, Cat. 18510), StemSpan H3000 (Stem Cell Technolo-
gies, Cat. 09800), and FACS rehydration/staining buffer (HBSS plus 4%
FBS). Human GM-CSF (Peprotech, Cat. 300-03), PMA (Sigma Technologies,
Cat. P8139), and ionomycin (Sigma Technologies, Cat. I0634) were used to
stimulate cells at the concentrations indicated in the text. A chemical JAK2 in-
hibitor (Calbiochem, Cat. 420099), the oral JAK2 inhibitor XL019 (Exelixis), and
the oral MEK inhibitor CI-1040 (Pfizer) were used as described. Antibodies
used for phosphoprotein detection were p-STAT5 Alexa 647 (BD Biosciences,
Cat. 612599, 10 ml per sample), CD34-PerCPcy5.5 (BD Biosciences, Cat.
347213, 7 ml per sample), CD38-PECy7 (BD Biosciences, Cat. 335790, 5 ml
per sample), CD11b-Pacific blue (BD Biosciences, Cat. 558123, 8 ml per sam-
ple), CD33-PE (BD Biosciences, Cat. 347787, 5 ml per sample), CD3-Pacific
blue (BD Biosciences, Cat. 558117, 5 ml per sample), and CD14-APC Cy7
(BD Biosciences, Cat. 557831, 5 ml per sample). Primary antibody against
p-ERK (p-p44/42 MAPK) was from Cell Signaling (Cat. 9101, used at 1:100).
FITC-labeled anti-rabbit IgG secondary antibody was from Jackson Immu-
noResearch (Cat. 711-096-152, used at 1:400). Primary antibody against
p-S6 was from Cell Signaling (Cat. 4856, used at 1:50). FITC-labeled anti-rab-
bit IgG secondary antibody was from Jackson ImmunoResearch (Cat. 711-
096-152, used at 1:400).
Freshly isolated or defrosted mononuclear cells were suspended in
prewarmed StemSpan H3000 at a concentration of 1–2 million cells/ml and
rested at 37C for 1 hr. The monocytic cell line U937, which harbors
a PTPN11 exon 3 mutation (178G/C, G60R), was used in each assay as
a positive control.
Cells were transferred as 1 ml aliquots into flow cytometry test tubes (BD
Biosciences, Falcon 2052) and stimulated with various concentrations of hu-
man GM-CSF (PeproTech, Cat. 300-03) for 15 min. Cells were fixed by adding
100 ml of 16%paraformaldehyde (PFA, ElectronMicroscopy Sciences) at room
temperature for 10 min. Cells were washed (centrifugation at 1800 rpm for
5 min) twice with phosphate-buffered saline (PBS) and permeabilized by re-
suspension in 2 ml ice-cold 95% methanol for 10 min. Cells were stored at
20C before staining for flow cytometry.
PFA-fixed, methanol-permeabilized cells were rehydrated by adding 2 ml
PBS andwashed (centrifugation at 2500 rpm for 5min) twice. Cells were resus-
pended in 500 ml FACS buffer (HBSS containing 4% FBS, HyClone) and incu-
bated at 4C for 2 hr.
Unconjugated primary antibodies were added at optimized concentrations
(p-ERK 1:100 or p-S6 1:50) and incubated at room temperature for 45 min.
Samples were washed (centrifugation at 2500 rpm for 5 min) once with
FACS buffer. Samples were stained in 100 ml final reaction volumes, using
PBS supplemented with 0.5% bovine serum albumin (Sigma, Cat. A2153) as
a diluent. Secondary and directly conjugated antibodies were added at opti-
mized concentrations and incubated in the dark at room temperature for
30 min. Samples were washed (centrifugation at 2500 rpm for 5 min) once
with PBS and analyzed on an LSR II flow cytometer (BDBiosciences) equipped
with 433 nm and 633 nm lasers.
Data Collection and Analysis
Data were collected using DIVA software (BD Biosciences) and analyzed using
Cytobank (http://www.cytobank.org/), an open-source flow cytometry storage
and analysis application developed in the Nolan and Levy laboratories at Stan-
ford University. Samples that showed a p-ERK response to PMAwere deemed
viable and used for analysis.
In Figure 1B, the percent of p-STAT5-responsive cells was determined by
drawing a gate using SSC and p-STAT5 to identify the percent of p-STAT5+
cells and scaling the response such that the maximum percent of p-STAT5+
cells was equivalent to 100 and the percent of p-STAT5+ cells at unstimulated
was equal to 0.
For Figure 3 and Figures S6 and S7, the normalized p-STAT5 (or p-ERK or p-
S6) response was calculated by transforming the raw data using the inverse
hyperbolic sine, part of the biexponential class of functions used for digital
flow cytometry data (Parks et al., 2006), and calculating a change in the 95th
percentile of p-STAT5 response between a GM-CSF-stimulated sample and
its unstimulated/basal state. The algorithm is outlined as follows:
For each patient, stain and collect samples stimulated with GM-CSF at the
following concentrations: unstimulated, 0.04 ng/ml, 0.16 ng/ml, 0.32 ng/ml,
2 ng/ml, and 10 ng/ml.
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i. Transform the raw data: sinh1(raw data/150)
ii. Identify live cells
iii. Calculate the 95th percentile of p-STAT5 in the transformed space
iv. Subtract this value from the 95th percentile of p-STAT5 of the un-
stimulated GM-CSF sample.
b. For each patient:
i. Calculate the range of p-STAT5 response to GM-CSF: max 95th
percentile p-STAT5 difference  min 95th percentile p-STAT5 dif-
ference
ii. Ignore patient if range of response is < 0.05
iii. Normalize the change in p-STAT5 such that the unstimulated sam-
ple is equal to 0 and the max difference is equal to 100: (difference
in p-STAT5/range of response) 3 100.
SUPPLEMENTAL DATA
The Supplemental Data include nine figures and two tables and can be found
with this article online at http://www.cancercell.org/cgi/content/full/14/4/335/
DC1/.
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